SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics ($CAPR) is trending following positive Phase 3 trial results for its DMD treatment, which has excited the community due to the potential for significant improvement in muscle and heart function. Discussions highlight the possibility of a short squeeze and a potential acquisition, with some traders setting ambitious price targets. The focus remains on the implications of the trial's success and potential market impact, particularly regarding those shorting the stock.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as the FTC requires the company to divest Spirit assets for its merger, sparking community debate about its impact. Some traders see the dip as a buying opportunity, while others express concern over the company's ability to hold gains and the ongoing regulatory scrutiny. The discussion includes broader concerns about cash flow and production relative to future earnings expectations.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending as the community debates the stock's recent surge, with discussions around potential market manipulation and short squeezes fueled by out-of-the-money call options. Some traders point to analyst upgrades and potential S&P 500 inclusion while others highlight concerns around the company's fundamentals and high short interest. The stock's unusual price action and high valuation relative to peers remain key talking points.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors discuss the potential impact of Marvell's acquisition of Celestial AI, a key partner, on POET's sales outlook and technology validation. The community highlights POET's unique optical interposer technology and patent portfolio, speculating on potential licensing agreements or even a full acquisition. Discussions also focus on the recent high trading volume and the possibility of a rebound to previous price levels.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is seeing increased community chatter, with some speculating about potential news or a catalyst for a breakout. Community members are discussing accumulation strategies and looking for whale activity to push the price higher. There's also broader discussion around Litecoin's utility and potential compared to other cryptocurrencies.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending due to a mix of factors including earnings results, a potential acquisition, and shifts in analyst ratings. Community discussions revolve around the company's AI infrastructure play and its move into optical interconnects with the possible acquisition of Celestial AI. Some traders are eyeing shorting opportunities amidst concerns of an overvalued stock, while others remain bullish on Marvell's long-term growth potential in the AI sector.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Galectin Therapeutics is trending as the community discusses potential FDA feedback on submitted data, with anticipation building around potential next steps for belapectin. Community members are pointing to positive biomarker data and highlighting CEO Joel Lewis's increased excitement, speculating about potential partnerships or a possible buyout. Investors are also actively monitoring short positions and overall trading volume.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending as traders discuss the potential impact of a possible executive order from the Trump administration to boost the robotics industry, as well as early data shared by Forbes. The community is actively highlighting breaking above the $10 mark as a positive sign and anticipating a squeeze, with some predicting a rise to $12 or higher soon. Broader robotics sector investments and partnerships, including those with NVDA and DASH, are also fueling optimism.

Pure Storage, Inc. engages in the business of delivering innovative and disruptive data storage, products, and services that enable customers to maximize the value of data. The firm is also involved in the provision of data storage and management with a mission to redefine the storage experience by simplifying how people consume and interact with data. The company was founded by John M. Hayes and John Colgrove in October 2009 and is headquartered in Santa Clara, CA.

Pure Storage Inc - Ordinary Shares - Class A

Pure Storage Inc

Pure Storage ($PSTG) is trending as investors digest its recent earnings report and a potential hyperscaler partnership, with community members debating whether the stock's pullback represents a buying opportunity or an overreaction. Bulls cite the company's strong position in AI-driven storage solutions and potential for further growth, while bears point to valuation concerns and mixed analyst ratings. The stock's high P/E ratio and sensitivity to growth expectations are also key talking points.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as investors discuss the potential impact of Tonmya's sales and pipeline development, specifically a possible "tsunami" in 2026. Community members are weighing the company's assets, cash position, and potential buyout offers, noting buyback activity and a possible announcement on the horizon. Some traders believe there is potential for a short squeeze, while others express concerns over dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The U.S. Food and Drug Administration on Wednesday granted traditional approval to Eli Lilly and Company’s Jaypirca for pre-treated adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.The agency approved the drug for patients who were previously treated with a covalent BTK inhibitor, a class of drugs that permanently bind to and block the Bruton's tyrosine kinase (BTK) protein, which is crucial for the survival of certain B-cell cancers like chronic lymphocytic leukemia.In December 2023, the FDA had granted accelerated approval to Jaypirca for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy. Accelerated approval is a conditional approval that requires the drug maker to conduct confirmatory studies after the drug is on the market to verify the clinical benefit.&nbsp;Get updates to this developing story directly on Stocktwits.

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Eli Lilly’s Jaypirca Granted Traditional FDA Approval In Treating Certain Cancers

The agency approved the drug for patients who were previously treated with a covalent BTK inhibitor. 

Equity

Frame 485.png

Get the daily email that keeps you tuned in and makes markets fun again.

Frame 484.png

The most relevant Indian markets intel delivered to you everyday.

cryptotwits - 800x800.png

Get the daily crypto email you’ll actually love to read. It's value-packed, data-driven, and seasoned with wit.

Frame 479.png

The best trade ideas and analysis from the Stocktwits community. Delivered daily by 8 pm ET.

Frame 486.png

For serious investors with a serious sense of humor.

Frame 487.png

High Relative Strength, Low Social Following

Eli Lilly’s Jaypirca Granted Traditional FDA Approval In Treating Certain Cancers

Latest News